Bli medlem
Bli medlem

Du är här

2016-06-07

DBV Technologies: DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board

----------------------------------
| Press Release |
| |
|Montrouge, France, June 7, 2016 |
----------------------------------

DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory BoardDr. Ebisawa strengthens DBV's scientific expertise and its global leadership
in developing treatments for food allergies

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
the appointment of Dr. Motohiro Ebisawa, MD, PhD, Director of Allergy at
Sagamihara National Hospital in Kanagawa, Japan, to its Scientific Advisory
Board. The contributions of Dr. Ebisawa, a renowned opinion leader in food
allergies, will continue to strengthen DBV's leadership in developing
transformational product candidates for the care and treatment of food
allergic patients around the world.

"We welcome Dr. Ebisawa to our Scientific Advisory Board, and we believe that
his appointment continues to bolster our leading medical and scientific
expertise,"
saidDr. Hugh Sampson
, Chief Scientific Officer, DBV Technologies."DBV's mission is to develop safe
and efficacious treatments for food
allergies, and as part of our pledge to patients, we are committed to
increasing our global footprint, including in Japan, where there is a
significant prevalence of food allergies."

Dr. Ebisawa is a leading expert in food allergies and currently serves as
Secretary General on the Board of Directors of the World Allergy Organization
(WAO), where he has served in different leadership roles since 2010. In
addition to his WAO tenure, Dr. Ebisawa serves on the Executive Board of
Directors of the Japanese Society of Allergology, is Chair of the Food
Allergy Committee of the Japanese Society of Pediatric Allergy and Clinical
Immunology, and is a member of the GINA Assembly and the Collegium
Internationale Allergogica (CIA).

"DBV's science- and patient-driven approach to finding a potential treatment
for food allergies marks an important turning point in our field, and I am
excited to be part of this effort. If approved, Viaskin Peanut could be a
major breakthrough for our patients, who have long awaited for an answer to
managing their disease,
" saidDr. Ebisawa

After graduating in medicine from The Jikei University School of Medicine in
Tokyo, Japan, Dr. Ebisawa completed his residency at Jikei University
Hospital, and was a visiting resident at St. Thomas Hospital in London,
England. He completed his postgraduate studies at The Jikei University School
of Medicine, where his earned his doctorate. He did postdoctoral fellowship
at Johns Hopkins University. After returning to his home country, he began
practice and research in food allergies. He has won multiple awards,
including theAllergy 2000 International Young Investigator Award
, and has authored numerous articles in peer-reviewed publications.

About DBV Technologies

DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically
active compounds to the immune system through intact skin. With this new
class of self-administered and non-invasive product candidates, the company
is dedicated to safely transforming the care of food allergic patients, for
whom there are no approved treatments. DBV's food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical
development of Viaskin Egg. DBV is also pursuing a human proof concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis,
and exploring potential applications of its platform in vaccines and other
immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York,
NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq
Global Select Market in the form of American Depositary Shares (each
representing one-half of one ordinary share) (Ticker: DBVT). For more
information on DBV Technologies, please visit our
website:www.dbv-technologies.com

Forward Looking Statements

This press release contains forward-looking statements, including statements
reflecting management's expectations for future financial and operational
performance and business outlook; and statements regarding our research and
development efforts and the commercial potential of our product candidates
generally. These forward-looking statements are not promises or guarantees
and involve substantial risks and uncertainties. Among the factors that could
cause actual results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and approvals,
the risk that historical preclinical results may not be predictive of future
clinical trial results, and the risk that historical clinical trial results
may not be predictive of future trial results. A further list and
description of these risks, uncertainties and other risks can be found in the
Company's regulatory filings with the French Autorité des Marchés Financiers,
the Company's Securities and Exchange Commission filings and reports,
including in the Company's Annual Report on Form 20-F for the year ended
December 31, 2015 and future filings and reports by the Company. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. DBV
Technologies undertakes no obligation to update or revise the information
contained in this Press Release, whether as a result of new information,
future events or circumstances or otherwise.

-------------------------------------------------------
| DBV Technologies Contact |
| Susanna Mesa |
| |
| |
|Senior Vice President, Strategy |
|+1 212-271-0861 |
|susanna.mesa@dbv-technologies.com |
| Media Contacts |
| Marion Janic, Rooney&Associates |
| |
|+1 212-223-4017 |
|mjanic@rooneyco.com |
| Media Contacts, Europe |
| |
|Caroline Carmagnol, Alize RP - Relation Presse |
| |
|+33 (0)6 64 18 99 59 |
|caroline@alizerp.com |
-------------------------------------------------------
PDF Version
http://hugin.info/156437/R/2018668/749266.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

HUG#2018668

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.